RESEARCH AT HIMALAYA Meta-analysis of the Efficacy and Safety of Liv.52® in the Management of Infective Hepatitis Aim To conduct a meta-analysis of 50 published study reports for the efficacy and short- and long-term safety of Liv.52 syrup and tablet in the management of hepatitis A Materials and Methods This meta-analysis included data from 50 clinical studies, in which 4490 patients (aged < 5–15 y) participated. Among them, 3007 patients received Liv.52 syrup and tablet for a mean period of 6 months, 785 patients received placebo, and the remaining patients received corticosteroids, multivitamins, or other treatments. The changes in the biochemical parameters (serum bilirubin [SB], serum glutamic oxaloacetic transaminase [SGOT], serum glutamic pyruvic transaminase [SGPT], serum alkaline phosphatase [SAP], serum albumin [SA], serum globulin [SG], and prothrombin time [PT]) from the baseline to values at the end of the study, and the total duration of clinical recovery were recorded. Incidence of adverse events during the study and patient compliance to the treatment were recorded. Results The elevated mean SB, SGOT, SGPT, and SAP levels and PT at entry significantly reduced in the Liv.52 group by the end of the study. The low SA and SG levels significantly increased in the Liv.52 group. The mean period required for total (symptomatic, clinical, and biochemical) recovery reduced significantly in the Liv.52 group compared with that in the placebo (Figure). No adverse events were observed in any trial, and the overall treatment compliance was excellent. Conclusion These findings suggest that Liv.52 syrup and tablet are safe and effective in the management of hepatitis A. Figure. Mean Period of Recovery in Hepatitis A Patients in the Control and Liv.52 Groups An excerpt of the clinical study conducted by Kolhapure SA et al published in the journal Medicine Update is featured here. at = 2.620; P = .0307; Significant Liv.52 0 5 10 15 20 25 Control a Day, n Himalaya Infoline • Vol 19 • No. 2 • May–Aug 2023 • 23
RkJQdWJsaXNoZXIy MjAwNDg=